159 related articles for article (PubMed ID: 10406188)
1. Clinical usefulness of serum matrix metalloproteinase-2 concentration in patients with chronic viral liver disease.
Murawaki Y; Yamada S; Ikuta Y; Kawasaki H
J Hepatol; 1999 Jun; 30(6):1090-8. PubMed ID: 10406188
[TBL] [Abstract][Full Text] [Related]
2. The proMMP-2 activation rate in patients with chronic viral liver disease.
Murawaki Y; Ikuta Y; Koda M; Okamoto K; Mimura K
Clin Chim Acta; 2002 Oct; 324(1-2):99-103. PubMed ID: 12204430
[TBL] [Abstract][Full Text] [Related]
3. Serum matrix metalloproteinase-3 (stromelysin-1) concentration in patients with chronic liver disease.
Murawaki Y; Ikuta Y; Okamoto K; Koda M; Kawasaki H
J Hepatol; 1999 Sep; 31(3):474-81. PubMed ID: 10488707
[TBL] [Abstract][Full Text] [Related]
4. Circulating matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as serum markers of fibrosis in patients with chronic hepatitis C. Relationship to interferon response.
Kasahara A; Hayashi N; Mochizuki K; Oshita M; Katayama K; Kato M; Masuzawa M; Yoshihara H; Naito M; Miyamoto T; Inoue A; Asai A; Hijioka T; Fusamoto H; Kamada T
J Hepatol; 1997 Mar; 26(3):574-83. PubMed ID: 9075665
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of tissue inhibitor of metalloproteinases-2 and of precursor form of matrix metalloproteinase-2 in patients with liver disease.
Ebata M; Fukuda Y; Nakano I; Katano Y; Fujimoto N; Hayakawa T
Liver; 1997 Dec; 17(6):293-9. PubMed ID: 9455735
[TBL] [Abstract][Full Text] [Related]
6. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer.
Endo K; Maehara Y; Baba H; Yamamoto M; Tomisaki S; Watanabe A; Kakeji Y; Sugimachi K
Anticancer Res; 1997; 17(3C):2253-8. PubMed ID: 9216697
[TBL] [Abstract][Full Text] [Related]
7. Serum tissue inhibitor of metalloproteinases in patients with chronic liver disease and with hepatocellular carcinoma.
Murawaki Y; Yamamoto H; Kawasaki H; Shima H
Clin Chim Acta; 1993 Sep; 218(1):47-58. PubMed ID: 8299219
[TBL] [Abstract][Full Text] [Related]
8. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis.
Walsh KM; Timms P; Campbell S; MacSween RN; Morris AJ
Dig Dis Sci; 1999 Mar; 44(3):624-30. PubMed ID: 10080160
[TBL] [Abstract][Full Text] [Related]
9. A one-step sandwich enzyme immunoassay for human matrix metalloproteinase 2 (72-kDa gelatinase/type IV collagenase) using monoclonal antibodies.
Fujimoto N; Mouri N; Iwata K; Ohuchi E; Okada Y; Hayakawa T
Clin Chim Acta; 1993 Nov; 221(1-2):91-103. PubMed ID: 8149645
[TBL] [Abstract][Full Text] [Related]
10. Elevated plasma levels of matrix metalloproteinase-9 (92-kd type IV collagenase/gelatinase B) in hepatocellular carcinoma.
Hayasaka A; Suzuki N; Fujimoto N; Iwama S; Fukuyama E; Kanda Y; Saisho H
Hepatology; 1996 Nov; 24(5):1058-62. PubMed ID: 8903375
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum type IV collagen: a sensitive indicator of the presence of cirrhosis in haemochromatosis.
George DK; Ramm GA; Walker NI; Powell LW; Crawford DH
J Hepatol; 1999 Jul; 31(1):47-52. PubMed ID: 10424282
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic potential of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as non-invasive markers of hepatic fibrosis in patients with HCV related chronic liver disease.
El-Gindy I; El Rahman AT; El-Alim MA; Zaki SS
Egypt J Immunol; 2003; 10(1):27-35. PubMed ID: 15719620
[TBL] [Abstract][Full Text] [Related]
13. Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis.
Murawaki Y; Ikuta Y; Idobe Y; Kawasaki H
J Gastroenterol Hepatol; 1999 Feb; 14(2):138-45. PubMed ID: 10029294
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C.
Boeker KH; Haberkorn CI; Michels D; Flemming P; Manns MP; Lichtinghagen R
Clin Chim Acta; 2002 Feb; 316(1-2):71-81. PubMed ID: 11750276
[TBL] [Abstract][Full Text] [Related]
15. Enhanced production and activation of progelatinase A mediated by membrane-type 1 matrix metalloproteinase in human papillary thyroid carcinomas.
Nakamura H; Ueno H; Yamashita K; Shimada T; Yamamoto E; Noguchi M; Fujimoto N; Sato H; Seiki M; Okada Y
Cancer Res; 1999 Jan; 59(2):467-73. PubMed ID: 9927064
[TBL] [Abstract][Full Text] [Related]
16. Significance of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in chronic hepatitis C patients.
Badra G; Lotfy M; El-Refaie A; Obada M; Abdelmonem E; Kandeel S; Fathy A
Acta Microbiol Immunol Hung; 2010 Mar; 57(1):29-42. PubMed ID: 20350877
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of serum matrix metalloproteinase (MMP)-9 to MMP-2 ratio as a biomarker in hepatocellular carcinoma.
Yeh HC; Lin SM; Chen MF; Pan TL; Wang PW; Yeh CT
Hepatogastroenterology; 2010; 57(97):98-102. PubMed ID: 20422881
[TBL] [Abstract][Full Text] [Related]
18. Dual expression of matrix metalloproteinase-2 and membrane-type 1-matrix metalloproteinase in fibrotic human livers.
Takahara T; Furui K; Yata Y; Jin B; Zhang LP; Nambu S; Sato H; Seiki M; Watanabe A
Hepatology; 1997 Dec; 26(6):1521-9. PubMed ID: 9397993
[TBL] [Abstract][Full Text] [Related]
19. Assessment of serum matrix metalloproteinases MMP-2 and MMP-9 after human liver transplantation: increased serum MMP-9 level in acute rejection.
Kuyvenhoven JP; Verspaget HW; Gao Q; Ringers J; Smit VT; Lamers CB; van Hoek B
Transplantation; 2004 Jun; 77(11):1646-52. PubMed ID: 15201662
[TBL] [Abstract][Full Text] [Related]
20. Evidence for altered hepatic matrix degradation in genetic haemochromatosis.
George DK; Ramm GA; Powell LW; Fletcher LM; Walker NI; Cowley LL; Crawford DH
Gut; 1998 May; 42(5):715-20. PubMed ID: 9659170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
